Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 2, 2009, Pages 233-237

  Ma, Hong ^a,b   Gomez, Victoria ^b   Lu, Liang ^b   Yang, Xiangjiu ^a   Wu, Xiaoyan ^c   Xiao, Shu Yuan ^b  

^a XIAMEN UNIVERSITY   (China)

^b ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Adiponectin; NAFLD pathogenesis; NAFLD pathology

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LIVER BIOPSY; MALE; MORBID OBESITY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 58849119649     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05548.x     Document Type: Article

References (23)

1. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003 37 : 917 23.
2. Powell EE, Cooksley WGE, Hanson R, Searle J, Halliday JW, Powell LW. The natural-history of nonalcoholic steatohepatitis - a follow-up-study of 42 patients for up to 21 years. Hepatology 1990 11 : 74 80.
3. Yamauchi T, Hara K, Kubota N et al. Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and antiatherogenic adipokine. Curr. Drug Targets. Immune. Endocr. Metabol. Disord. 2003 3 : 243 54.
4. Berg AH, Combs TP, Du XL, Brownlee M, Scherer P. The adipocyte secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 2001 7 : 947 53.
5. Ouchi N, Kihara S, Arita Y et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001 103 : 1057 63.
6. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem. Biophys. Res. Commun. 2004 323 : 630 5.
7. Xu AM, Wang Y, Keshaw H, Xu LY, Lam KSL, Cooper GJS. The fat derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 2003 112 : 91 100.
8. Aygun C, Senturk O, Hulagu S et al. Serum levels of hepatoprotective peptide adiponectin in non-alcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 2006 18 : 175 80.
9. Mehmet Y, Ibrahim H B, Huseyin A et al. Serum adipokine and ghrelin levels in nonalcoholic steatohepatitis. Mediators Inflamm. 2006 6 : 1 5.
10. Yamauchi T, Kamon J, Ito Y et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003 423 : 762 9.
11. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999 94 : 2467 74.
12. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004 40 : 46 54.
13. Bugianesi E, Pagotto U, Manini R et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J. Clin. Endocrinol. Metab. 2005 90 : 3498 504.
14. Yoda-Murakami M, Taniguchi M, Takahashi K et al. Change in expression of GBP28/adiponectin in carbon tetrachloride-administrated mouse liver. Biochem. Biophys. Res. Commun. 2001 285 : 372 7.
15. Kaser S, Moschen A, Cayon A et al. Adiponectin and its receptors in non-alcoholic Steatohepatitis. Gut 2005 54 : 117 21.
16. Uribe M, Zamora-Valdés D, Moreno-Portillo M et al. Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease. Ann. Hepatol. 2008 7 : 67 71.
17. Vuppalanchi R, Marri S, Kolwankar D, Considine RV, Chalasani N. Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J. Clin. Gastroenterol. 2005 39 : 237 42.
18. Oana F, Takeda H, Matsuzawa A, Akahane S, Isaji M, Akahane M. Adiponectin receptor 2 expression in liver and insulin resistance in db/db mice given a beta3-adrenoceptor agonist. Eur. J. Pharmacol. 2005 518 : 71 6.
19. Tacke F, Wustefeld T, Horn R et al. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J. Hepatol. 2005 42 : 666 73.
20. Kamada Y, Tamura S, Kiso S et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003 125 : 1796 807.
21. Ouchi N, Kihara S, Arita Y et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000 102 : 1296 301.
22. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J. Clin. Endocrinol. Metab. 2002 87 : 2764 9.
23. Fumihiko M, Hiroyuki O, Masahiro K et al. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem. Biophys. Res. Commun. 2007 358 : 1091 5.